Thursday, 20th November 10.30-10.45 Opening remarks Carlos Camps, Hospital General Universitario, Valencia Past, present and future of the Spanish Lung Cancer Group SESSION 1 Cancer biology and lung cancer origins: improving knowledge for better treatment 10.45-10.55 Is Helicobacter Pylori a cause of lung cancer? 10.55-11.05 HPV in exhaled breath condensate of lung cancer patients 11.05-11.15 Role of the SWI/SNF and MYC/MAX pathways in lung cancer development 11.15-11.25 Complement activation pathway elements as diagnostic markers and therapeutic targets in NSCLC Luis Montuenga, Universidad de Navarra, Pamplona (Navarra) Florentino Hernando Trancho, Hospital Clínico San Carlos, Madrid Cristina Teixidó, Pangaea Biotech, Barcelona Cristina Queralt, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Montserrat Sánchez-Céspedes, Instituto de Investigación Biomédica de Bellvitge, L Hospitalet de Llobregat (Barcelona) Rubén Pío, Centro de Investigación Médica Aplicada, Universidad de Navarra, Pamplona (Navarra) 11.25-11.35 Moving forward to solving the problem of predicting relapse in early NSCLC patients 11.35-11.50 How to improve the outcome of SCLC patients: a message from a basic researcher 11.50-12.00 SESSION 2 Liquid biopsy 12.00-12.10 Circulating tumor cells in lung cancer. What is the reality? New promises in mrna and mutational analysis 12.10-12.20 Ernest Nadal, ICO, Hospital Duran i Reynals, L Hospitalet de Llobregat (Barcelona) Jun Yokota, Institut de Medicina Predictiva i Personalitzada del Càncer, Badalona (Barcelona) Federico Rojo, Fundación Jiménez Díaz, Madrid Alexandra Voutsina, University of Crete, School of Medicine, Heraklion, Greece EGFR, KRAS, BRAF, MET, PIK3CA mutations and ALK translocations in blood platelets. A novel approach for diagnosis and monitoring Thomas Würdinger, VU University Medical Center, Amsterdam, The Netherlands 12.20-12.30 EGFR mutations in circulating tumor DNA. The EURTAC experience 12.30-12.40 KRAS and BRAF mutations in circulating tumor DNA Clara Mayo, Instituto Univ. USP Dexeus, Barcelona
Plenary Session & VII Educational Symposium of the Spanish Lung Cancer Group 12.40-12.50 The role of SNPs in NSCLC 12.50-13.00 Taking cancer cells out of circulation. Induction of patient-specific tumors in mice and prediction of response to chemotherapy 13.00-13.10 Eloísa Jantus, Hospital General Universitario, Valencia Alberto Villanueva, ICO, Institut d Investigació Biomèdica de Bellvitge (Barcelona) Metabolomics by NMR facilitates the non-invasive diagnosis and staging of NSCLC Antonio Pineda, Centro de Investigación Príncipe Felipe, Valencia 13.10-13.20 13.20-15.00 Lunch SESSION 3 Die another day: Targeted therapies in KRAS driven NSCLC KRAS mutations linked to poor prognosis and resistance to therapy 15.00-15.10 State of art KRAS mutations in lung cancer 15.10-15.20 KRAS mutations associated with folate pathway activity (tumor expression of MTHFD2 predicts response to pemetrexed) 15.20-15.30 15.30-15.40 15.40-15.50 15.50-16.05 16.05-16.15 Enric Carcereny, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Rosario García-Campelo, Complejo Hospitalario Univ. A Coruña Autophagy dependence in KRAS driven tumors with production of secreted factors and Pivotal role for SMYD3 in the regulation of oncogenic Ras signaling Niki Karachaliou, Hospital Univ. Quirón Dexeus, Barcelona Small molecule inhibition of KRAS-PDE interaction impairing oncogenic KRAS signaling Roger Estrada, Universitat Ramon Llull, Barcelona Synthetic lethal combinations in KRAS NSCLC cell lines combining gefitinib/ erlotinib with an AXL inhibitor. Compound 16 Silvia García-Román, Universitat Ramon Llull, Barcelona What is the usefulness of p53 mutations in large cohorts of EGFR-mutated, EGFR TKI treated, or non-mutated chemotherapy treated lung cancer patients? Miguel Ángel Molina, Hospital Univ. Quirón Dexeus, Barcelona
Plenary Session & VII Educational Symposium of the Spanish Lung Cancer Group SESSION 4 The renaissance of customizing chemotherapy and targeted therapy 16.15-16.25 New clues in ERCC1 prompting the PIPSeN study olaparib maintenance in platinum-sensitive NSCLC Juan Coves, Hospital Son Llàtzer, Palma de Mallorca Manuel Cobo, Hospital Univ. Carlos Haya, Málaga Sophie Postel-Vinay, Institut Gustave Roussy, Villejuif, France 16.25-16.35 The predictive role of BRCA1/53BP1 and HERC2 mrna in advanced NSCLC patients 16.35-16.45 The emerging role of bridging molecules in BRCA complexes. Key role of PALB2 in the BREC 16.45-16.55 Results of BRCA pathway analysis in the NATCH study 16.55-17.05 The burning need to repurpose drugs in NSCLC and SCLC 17.05-17.20 Biomarkers for exploiting the vulnerabilities of DNA repair deficiency or proficiency 17.20-17.30 17.30-18.00 Coffee Break SESSION 5 Second and third generation EGFR TKIs 18.00-18.10 State of the art in second generation EGFR TKIs: afatinib & dacomitinib 18.10-18.20 State of the art in third generation EGFR TKIs: AZ9291, CO-1686, HM61713 18.20-18.30 Lessons from the BELIEF 18.30-18.40 Synthetic lethal therapy with EGFR TKIs plus repurposing drugs in EGFR mutant lung cancer customized by BIM mrna expression 18.40-18.55 18.55 Laura Bonanno, Istituto Oncologico Veneto, Padova, Italy Niki Karachaliou, Hospital Univ. Quirón Dexeus, Barcelona Imane Chaib, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Mariacarmela Santarpia, Istituto Europeo di Oncologia, Messina, Italy Emilio Esteban, Hospital Universitario Central de Asturias, Oviedo (Asturias) Manuel Dómine, Fundación Jiménez Díaz, Madrid Teresa Morán, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Pilar Lianes, Hospital de Mataró, Mataró (Barcelona) Santiago Ponce, Hospital Univ. 12 de Octubre, Madrid Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Characterization of irreversible EGFR mutant selective EGFR inhibitors. What we need to know. Roger Estrada, Universitat Ramon Llull, Barcelona
Friday, 21st November 08.00-09.00 SLCG Plenary Session SESSION 6 Recent result in advanced NSCLC 09.00-09.15 Immune based anti-tumor therapies. PD1 & PDL1 blockade 09.15-09.30 Antiantiogenic strategies 09.30-09.45 ALK Target Therapies 09.45-09.55 SESSION 7 Diagnostic clinical genome and exome sequencing 09.55-10.05 Sequencing of the genome or exome for clinical applications 10.05-10.15 Actionable diagnosis of lung cancer by next generation sequencing 10.15-10.25 Treatment of ROS1 lung cancer patients: the EUCROSS trial 10.25-10.35 Opportunities to treat other driver alterations such as RET and NTRK 10.35-10.45 Treatment of BRAF mutant NSCLC patients 10.45-11.00 Current practice in diagnostic clinical genome 11.00-11.10 11.10-11.30 Coffee break Jürgen Wolf, Center for Integrated Oncology, University of Cologne, Germany Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Enriqueta Felip, Hospital General Vall d Hebron, Barcelona Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona Amelia Insa, Hospital Clínico Universitario, Valencia Angel Artal, Hospital Univ. Miguel Servet, Zaragoza Natividad Martínez, Hospital General Universitario, Elche (Alicante) Trever Bivona, University of California, San Francisco (California), USA Julie George, Center for Integrated Oncology, University of Cologne, Germany Jürgen Wolf, Center for Integrated Oncology, University of Cologne, Germany Ignatius Ou, University of California Irvine Medical Center, Orange (California), USA José Miguel Sánchez, Hospital Univ. de La Princesa, Madrid Fernando López-Ríos, Centro de Investigaciones Oncológicas Clara Campal, Madrid
Plenary Session & VII Educational Symposium of the Spanish Lung Cancer Group SESSION 8 Moving forward to improving curability in locally advanced NSCLC. What s new? 11.30-11.40 Salvage surgery following chemoradiotherapy 11.40-11.50 How can we reconcile chemoradiotherapy with or without surgery for locally advanced NSCLC? Felipe Cardenal, ICO, Hospital Duran i Reynals, L Hospitalet de Llobregat (Barcelona) Manuel de las Heras, Hospital Clínico San Carlos, Madrid Laura Romero, Hospital Univ. Vall d Hebron, Barcelona 11.50-12.00 New opportunities to treat: RENO trial 12.00-12.10 Novel expectations in chemoradiotherapy 12.10-12.20 SESSION 9 Novel perspectives in management of early stage NSCLC 12.20-12.30 SCAT results of customized adjuvant chemotherapy in state II and III resected NSCLC patients Dolores Isla, Hospital Clínico Univ. Lozano Blesa, Zaragoza Wilfried Eberhardt, West German Cancer Center, Essen, Germany Marcelo Jiménez, Hospital Universitario de Salamanca José Luis González Larriba, Hospital Clínico San Carlos, Madrid Bartomeu Massutí, Hospital General Universitario, Alicante 12.30-12.45 Management of stage I NSCLC patients 12.45-13.00 What we can expect in the next two years. The hope for SCLC and increased survival in NSCLC patients Javier de Castro, Hospital Univ. La Paz, Madrid Mariano Provencio, Hospital Univ. Puerta de Hierro, Majadahonda (Madrid) 13.00-13.15 State of the art in mesothelioma 13.15-13.25 13.25-13.45 Closing Remarks Noemí Reguart, Hospital Clínic Universitari, Barcelona
Scientific Committee Carlos Camps, Hospital General Universitario, Valencia Enric Carcereny, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Felipe Cardenal, ICO, Hospital Duran i Reynals, L Hospitalet de Llobregat (Barcelona) Manuel Cobo, Hospital Univ. Carlos Haya, Málaga Juan Coves, Hospital Son Llàtzer, Palma de Mallorca Javier de Castro, Hospital Univ. La Paz, Madrid Manuel Dómine, Fundación Jiménez Díaz, Madrid Rosario García Campelo, Complejo Hospitalario Universitario, A Coruña José Luis González Larriba, Hospital Clínico Univ. San Carlos, Madrid Florentino Hernando-Trancho, Hospital Clínico Univ. San Carlos, Madrid Dolores Isla, Hospital Clínico Univ. Lozano Blesa, Zaragoza Eloísa Jantús, Hospital General Universitario, Valencia Margarita Majem, Hospital de la Santa Creu i Sant Pau, Barcelona Bartomeu Massutí, Hospital General Universitario, Alicante Teresa Morán, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) Mariano Provencio, Hospital Univ. Puerta de Hierro, Majadahonda (Madrid) Noemí Reguart, Hospital Clínic Universitari, Barcelona Delvys Rodríguez, Hospital Univ. Insular de Gran Canaria, Las Palmas Rafael Rosell, ICO, Hospital Univ. Germans Trias i Pujol, Badalona (Barcelona) José Javier Sánchez, Universidad Autónoma de Madrid José Miguel Sánchez, Hospital Univ. de la Princesa, Madrid Miquel Taron, Pangaea Biotech, Barcelona
Venue Hotel NH Eurobuilding Sala Madrid c/ Padre Damián, 23 28036 Madrid Holding a badge will be required to access the meeting room Language Lectures will be delivered in English or Spanish. Credits Accreditation requested to the Consell Català de Formació Continuada de les Professions Sanitàries Supporting Companies Symposium Secretariat Monasterios de Suso y Yuso 34, 4-14-2 28049 Madrid Tel.: +34 91 372 02 03 E-mail: gecp2014@doctaforum.com www.doctaforum.com/gecp